Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2009

View Archived Issues

Trabectedin beneficial in some castration-resistant prostate cancer patients

Optimer to file MAA with EMEA for fidaxomicin in CDI

Novel EGFR inhibitors discovered by Astellas researchers

AstraZeneca discloses new mTOR inhibitors

New SCD inhibitors for obesity imparted in recent GSK patent

Schering-Plough imparts new HCV NS3/NS4 protease inhibitors

Sonexa Therapeutics evaluates efficacy and safety of ST-101 in Alzheimer's disease

Darifenacin reduces incontinence in overactive bladder patients

2008 highlights at Chugai

Nabriva Therapeutics claims new pleuromutilin derivatives as antimicrobials

Gemin X initiates phase II obatoclax trial in combination with chemotherapy

FDA approves Copaxone for patients with a first clinical event of MS

AZD-4877 shows antitumor activity in human bladder cancer models

AV-951 shows activity in phase II trial for renal cell carcinoma

Immunomodulation via Toll-like receptors may be beneficial in Alzheimer's disease

Boston Scientific launches Taxus Liberte paclitaxel-eluting stent in Japan

First patient treated in novel immunotherapeutic vaccine trial

EyeGate completes phase II EGP-437 trial for dry eye syndrome

FDA accepts IND application for Tigris Pharmaceutical's GGTI-2418

FDA clears Cellectar's IND application for 131I-CLR1404

Serentis initiates phase II trial of SRD-174 for pruritus in atopic dermatitis patients

Xoma initiates phase IIa XOMA-052 trial in patients with rheumatoid arthritis

Enobia completes enrollment in clinical trial of ENB-0040 in infantile hypophosphatasia

FDA removes clinical hold from Aastrom's phase II IMPACT-DCM trial

Acura's NDA for Acurox accepted by FDA for filing with priority review

Menarini launches CV Therapeutics' Ranexa in the U.K. and Germany

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026